Dry age-related macular degeneration is the nonexudative form of AMD and is characterized by drusen accumulation and gradual central vision decline. It is the more common AMD subtype and can progress over time to advanced geographic atrophy or to wet AMD in a subset of patients. The disease primarily affects older adults.
Ocular Therapeutix's experimental drug Axpaxli showed superior vision maintenance compared to Regeneron's Eylea in a late-stage wet AMD trial. Meanwhile, Ocugen reported 12-month data showing its gene therapy OCU410 reduced geographic atrophy lesions by 31%, though less than earlier interim results. Both companies are advancing toward regulatory submissions and further clinical development.
Ocugen reported Phase 2 data for its geographic atrophy gene therapy OCU410 showing 31% lesion growth reduction versus control. The company plans Phase 3 initiation in Q3 2026 and maintains its goal of three BLA filings in three years. Shares fell 11.48% following the data release which trailed earlier interim results.
Ocugen will host a conference call on March 4, 2026 at 8:30 a.m. ET to discuss fourth quarter and full year 2025 financial results and provide a business update, with a pre-market earnings announcement the same day.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT06557460 |
A Phase IIb Randomized, Multicenter Trial of Subretinal CPCB-RPE1 in Advanced Dry AMD (Geographic Atrophy) |
RECRUITING | PHASE2 |
| NCT06536062 |
Age-related Macular Degeneration of Atrophic Type Treated With Umbilical Cord Blood Enriched With Platelet Plasma. |
RECRUITING | NA |
| NCT06351605 |
A Registry Study to Assess Photobiomodulation in Dry Age-Related Macular Degeneration (EUROLIGHT) (EUROLIGHT) |
RECRUITING | |
| NCT06229665 |
Study of Photobiomodulation to Treat Dry Age-Related Macular Degeneration (LIGHTSITEIIIB) |
ACTIVE_NOT_RECRUITING | PHASE2/PHASE3 |
| NCT06165068 |
Effects of Antiplatelet and Antioxidant Agents on Drusen Progression: A Pilot, Prospective Cohort Study |
RECRUITING | PHASE3 |
| NCT05797896 |
Investigating Geographic Atrophy Insights (i-GAIN) Natural History Study |
ACTIVE_NOT_RECRUITING | |
| NCT05706896 |
Atrophic Age-related Macular Degeneration Treated With Intravitreal Injections of Umbilical Cord Blood Platelet-rich Plasma |
RECRUITING | NA |
| NCT05667688 |
Pharmacokinetics and Pharmacodynamics Study of LBS-008 in Healthy Volunteers Aged 50-85 |
COMPLETED | PHASE1 |
| NCT05536752 |
QA102 Phase II Study in Subjects With Dry AMD |
COMPLETED | PHASE2 |
| NCT05447650 |
Microcurrent Stimulation Therapy for Nonexudative Age-related Macular Degeneration (i-SIGHT) |
COMPLETED | NA |
